世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い



アジア太平洋地域の慢性特発性便秘症治療薬市場予測 2018-2026年

ASIA PACIFIC CHRONIC IDIOPATHIC CONSTIPATION (CIC) DRUG MARKET FORECAST 2018-2026

 

出版社 出版日電子媒体価格ページ数
Inkwood Research
インクウッドリサーチ
2018年5月 US$ 1,250
シングルユーザライセンス
65p

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートはアジア太平洋地域の慢性特発性便秘症治療薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Description

KEY FINDINGS
The Asia-Pacific chronic idiopathic constipation drug market is predicted to expand at a CAGR of 10.12% over the forecast period of 2018-2026. The region is considered to be the most promising and lucrative market for CIC drugs and is expected to grow at a considerable pace over the projected years.
MARKET INSIGHTS
The Asian CIC drug market can be segmented by the type of drug and by the type of prescription. The drug lubiprostone is dominating the drug segment closely followed by the drug linaclotide. By prescription type, over the counter drugs are more popular as they can be obtained without a doctor’s prescription. The major driver increasing growth in the Asian market is the modern dietary habits such as intake of foods rich in animal fats, especially dairy products, eggs and meat or foods that have refined sugar and low fibre. Although the market looks promising for the coming years, factors like alternate surgical treatments and the lack of awareness about such drugs in the masses are acting as restraints for market growth.
COMPETITIVE INSIGHTS
Ferring International Center S.A, Progenics Pharmaceuticals Inc Chugai Pharmaceutical, Theravance Biopharma Inc, Allergens, Synergy Pharmaceuticals, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, GlaxoSmithKline, Pfizer, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Roche Holding Ag ,Merck Sharp & Dohme, Bayer Ag, and Sucampo Pharmaceuticals Inc, are some of the leading companies in this market.



目次

目次はEメールでお送りいたします。データリソースまでお申し付けください。

 

COPYRIGHT(C) 2011-2019 DATA RESOURCES, Inc. ALL RIGHTS RESERVED.